The farnesoid X receptor (FXR) is a nuclear receptor that regulates glucose and lipid homeostasis, inhibits inflammation and fibrosis, and thus is a promising target in NASH. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.